Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | LCK | P06239 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544192 | 0.88 | CASP3 (0.60) | RAB9AMAPTNPC1LCKGHSR | |
| SCHEMBL544638 | 0.86 | GHSR (0.60) | RAB9AMAPTNPC1PKMGHSR | |
| SCHEMBL544856 | 0.84 | TUBB4A (0.64) | RAB9AMAPTNPC1PKMGHSR | |
| SCHEMBL544191 | 0.82 | LCK (0.60) | RAB9AMAPTNPC1LCKKMT2A | |
| SCHEMBL544513 | 0.82 | CASP3 (0.62) | RAB9AMAPTNPC1LCKKMT2A | |
| SCHEMBL544395 | 0.82 | ALDH1A1 (0.62) | RAB9AMAPTNPC1PKMGHSR | |
| SCHEMBL543917 | 0.81 | GHSR (0.47) | RAB9AMAPTNPC1LCKPKM | |
| SCHEMBL544665 | 0.81 | GHSR (0.58) | RAB9AMAPTNPC1LCKPKM | |
| SCHEMBL544976 | 0.80 | GHSR (0.49) | RAB9AMAPTNPC1LCKPKM | |
| SCHEMBL544033 | 0.80 | GHSR (0.52) | MAPTLCKPKMGHSRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | RAB9A 3640/4885MAPT 1307/4885NPC1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.